This clinical trial is focused on studying the treatment of COVID-19, a disease caused by the SARS-CoV-2 virus, which can lead to respiratory symptoms and other health issues. The treatment being tested is a medication called Bemcentinib, which is taken in capsule form. Bemcentinib is a type of drug known as a receptor tyrosine kinase inhibitor, which means it works by blocking certain proteins that may help the virus spread in the body. The study will compare the effects of Bemcentinib combined with standard care to a placebo combined with standard care in patients who are hospitalized with moderate COVID-19.

The purpose of the study is to evaluate how effective Bemcentinib is in improving the condition of patients with moderate COVID-19. Participants in the study will receive either Bemcentinib or a placebo, along with the usual care provided in hospitals. The study will monitor the patients’ health over a period of time to see if there are any changes in their condition, such as improvement or worsening of symptoms. The study will also look at other factors, such as how quickly patients recover and any side effects they may experience.

Throughout the study, various health indicators will be assessed, including the patients’ disease state on a scale used by the World Health Organization (WHO) and the levels of oxygen in their blood. The study will also track the occurrence of any serious health events and the time it takes for patients to be discharged from the hospital. By the end of the study, researchers hope to gather valuable information about the potential benefits and safety of using Bemcentinib to treat COVID-19.